TABLE 2.

Viable counts of C. difficile in fecal cultures supplemented with NDO and clindamycin

TreatmentC. difficile viable counts (log10CFU/ml)a
0 h6 h12 h24 h48 h
Control5.8 ± 0.15.8 ± 0.15.8 ± 0.15.8 ± 0.45.3 ± 0.4
NDO treatment group
    FOS5.7 ± 0.15.6 ± 0.15.4 ± 0.15.2 ± 0.14.4 ± 0.6
    GOS5.7 ± 0.15.2 ± 0.35.0 ± 0.24.7 ± 0.24.8 ± 0.2
    Inulin5.8 ± 0.15.7 ± 0.25.2 ± 0.44.1 ± 0.54.4 ± 0.3
    Mean5.7 ± 0.15.6 ± 0.25.3 ± 0.4b4.9 ± 0.54.5 ± 0.7
Clindamycin control5.8 ± 0.16.7 ± 0.27.6 ± 0.47.2 ± 0.27.0 ± 0.7
Clindamycin + NDO treatment group
    Clindamycin + FOS5.7 ± 0.17.2 ± 0.48.1 ± 0.28.3 ± 0.57.7 ± 0.1
    Clindamycin + GOS5.7 ± 0.16.6 ± 0.27.7 ± 0.27.4 ± 0.17.3 ± 0.4
    Clindamycin + inulin5.8 ± 0.16.9 ± 0.27.8 ± 0.28.0 ± 0.56.2 ± 0.2
    Mean5.7 ± 0.16.9 ± 0.47.7 ± 0.58.1 ± 0.47.0 ± 0.6
  • a Mean ± standard deviation (n = 3).

  • b There was a significant difference between the control and the NDO treatment group as determined by analysis of variance (P ≤ 0.05).